Lori Wenz, MSN, AGNP-C, BC-ADM, FOMA’s Post

🩺 Translating Diabetes Care: A New Horizon for Type 2 Diabetes Management A new technique may end the need for insulin injections that many type 2 diabetes patients rely on. The "Recellularization via Electroporation Therapy" (ReCET), a technology targeted using electric pulses to enhance natural insulin sensitivity within the body, has achieved a minimally invasive procedure that paired ReCET with the type 2 diabetes drug semaglutide, showing early results able to limit the administration of insulin by 86% over a two-year period in patients. ScienceDaily New Atlas This is an exciting new treatment that is sure to elicit a better response from the body to its own insulin, making this therapy possibly more viable and economical. Investigators hope to conduct larger trials, but for now, it is an exciting step forward in diabetes care which could revolutionize how millions manage their health Diabetes UK American Diabetes Association Diabetes and Its Complications  #DiabetesResearch #HealthcareInnovation #Type2Diabetes #DiabetesBreakthrough #MedicalTechnology #Endocrinology #HealthcareTransformation #DiabetesCure

New findings show that tirzepatide, an injectable weight-loss drug sold under the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period compared with a placebo. The multi-institutional study, led by Dr. Louis Aronne of Weill Cornell Medicine and NewYork-Presbyterian Hospital, showed that after 176 weeks of treatment, only 1.3% of patients who were both obese and prediabetic and took the drug in any of three doses, progressed to type 2 diabetes. Among patients taking a placebo, 13.3% progressed to type 2 diabetes. Full story: https://bit.ly/4eQgN22

ATEROMA (ASOBAT)| 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ ----------------------------------------------- 𝐁𝐞𝐭𝐭𝐞𝐫 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐝𝐢𝐚𝐛𝐞𝐭𝐢𝐜 𝐤𝐢𝐝𝐧𝐞𝐲 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐛𝐲 '𝐬𝐭𝐚𝐜𝐤𝐢𝐧𝐠' 𝐝𝐫𝐮𝐠𝐬 𝐟𝐫𝐨𝐦 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐜𝐥𝐚𝐬𝐬𝐞𝐬. Aggressive treatment of diabetic kidney disease (DKD) can not only slow the progression of RD to kidney failure, but, if used early enough in RD, can also stabilize and/or reverse the deterioration of kidney function. ► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Bell DSH, Jerkins T The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different clases. Diabetes Obes Metab 2024 Mar 22; [EPub Ahead of Print] ► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://lnkd.in/eyDmDJVy ----------------------------------------------- ✔ 𝗧𝗲𝗹𝗲𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲: https://lnkd.in/dhU-Um2K  

🚀 Germany Takes Bold Step in Diabetes Care! 🇩🇪 The Federal Joint Committee (G-BA) has launched a comprehensive assessment of insulin icodec, a groundbreaking formulation aimed at transforming the treatment landscape for individuals with type 1 diabetes. 🔍 Key Highlights: - Potential for more stable glucose control with fewer injections! - Improved patient adherence could lead to significant cost savings. - Simplified insulin management may enhance quality of life for patients. This thorough evaluation will analyze clinical efficacy, safety, and economic implications, paving the way for data-driven recommendations that could revolutionize diabetes care in Germany. Stay tuned as we await insights that will shape reimbursement policies and treatment protocols! 💡 👉 Click the link to learn more about this exciting development! #DiabetesCare #G-BA #GermanyHealth #HealthcareInnovation #InsulinIcodec #RegulatoryAgencies #Type1Diabetes #MarketAccess #MarketAccessToday

📣 Landmark Trial Summaries, Presented by InpharmD The QWINT-2 trial evaluated efsitora, a once-weekly basal insulin, compared to daily degludec in patients with type 2 diabetes. After 52 weeks, efsitora achieved a mean HbA1c reduction of 1.26%, compared to a 1.17% reduction with degludec (difference: -0.09%, 95% CI, -0.22 to 0.04), meeting pre-specified non-inferiority criteria. Secondary endpoints included time in range and TRIM-D scores, indicating no significant difference between treatment groups. These data provide evidence for the potential utility of once-weekly basal insulin regimens as an alternative to daily administration in achieving comparable glycemic outcomes. Read more on our blog: https://lnkd.in/e8_dicvY #stayinformedwithInpharmD

The advent of SGLT-2 inhibitors in clinical practice has substantially changed the treatment paradigm of people with type 2 diabetes. An unprecedented success story is unfolding in front of our eyes, but let’s be clear - victory shouldn’t be declared yet. Closing the gap between science and clinical practice seems even more important because of the sheer number of patients that are to benefit from these drugs. Find the full story in our recent commentary in DOM https://lnkd.in/dd_BhR4B #diabetes, #SGLT2, #realworldevidence, #diabetesdrugs 

Do we need to re-think how we proceed with people who screen positive for #T1D markers? "With the approval of teplizumab by the US Food and Drug Administration in 2022 to delay type 1 diabetes in people at stage 2, there is a need to refine the definition and accuracy of type 1 diabetes staging." "Time to reframe the disease staging system for type 1 diabetes" Read: https://lnkd.in/guci4jBK ##type1diabetes #health #healthcare #science #MedicalResearch #NDAM #HCPs

Another milestone for PolTREG. We are announcing positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes (T1D). “At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG S.A. Chief Executive Officer.   Here are the main findings, found over a period of up to 12 years during which patients were monitored: ☑ Patients who received PTG-007 continued to secrete insulin, while untreated patients in the control group did not, ☑ Safety measures showed no significant difference in the health status of patients who received Treg therapy compared to the control group, ☑ The duration of disease remission was significantly longer in patients who received PTG-007 compared to the control group.   No other company currently can show similar long-term safety results of Treg therapy in T1D. This is a significant competitive advantage, and paves the way for the launch of a pivotal Phase 2/3 study of PTG-007 – a final step before seeking market authorization.   Read our press release here: https://lnkd.in/dNEyDRK7   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

I want to make sure everyone is aware of the great clinical drug information resources available at no cost such as the landmark QWINT-2 trial summary below. Follow InpharmD for more!

With PPARs, more (isoforms) is better A great article by M. P. Cooreman, L. Vonghia, S. M. Francque: MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists - ScienceDirect "Single PPAR agonists are approved for hypertriglyceridemia (PPARα) and T2D (PPARγ), but these, as well as dual PPAR agonists, have shown mixed results as anti-MASH treatments in clinical trials. Agonists of all three PPAR isoforms have the potential to improve the full disease spectrum from insulin resistance to fibrosis, and correspondingly to improve cardiometabolic and hepatic health, as has been shown (phase II data) with the pan-PPAR agonist lanifibranor."